Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
BETOPTIC vs PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Propranolol is a non-selective beta-adrenergic receptor antagonist blocking beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release; hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
Propranolol hydrochloride 40-80 mg/hydrochlorothiazide 25-50 mg orally twice daily. Maximum propranolol 640 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Propranolol: 3-6 hours (terminal half-life); can increase with hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal half-life); prolonged in renal impairment.
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Propranolol: <1% excreted unchanged in urine; extensively metabolized in liver, metabolites excreted renally. Hydrochlorothiazide: ≥95% excreted unchanged in urine via renal tubular secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker